News | April 01, 2025
Akums launches Ripasudil + Timolol combination for glaucoma treatment
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
Branded formulation business continues to perform well across domestic and export markets
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Chobhe brings over 30 years of extensive experience in quality and regulatory management within the pharmaceutical industry
e brings over 27+ years of rich pharmaceutical experience
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
Subscribe To Our Newsletter & Stay Updated
